All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
09Jul20 07:00 RNS AstraZeneca -0.22% Health £112,186m Brilinta granted US FDA Priority Review for stroke
08Jul20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza approved in the EU for pancreatic cancer
01Jul20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
30Jun20 15:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
30Jun20 07:00 RNS AstraZeneca -0.22% Health £112,186m Selumetinib granted Japan orphan drug designation
17Jun20 15:03 RNS AstraZeneca -0.22% Health £112,186m Holding(s) in Company
17Jun20 15:00 RNS AstraZeneca -0.22% Health £112,186m Holding(s) in Company
15Jun20 07:00 RNS AstraZeneca -0.22% Health £112,186m Agreement to Supply Europe with COVID-19 Vaccine
11Jun20 07:00 RNS AstraZeneca -0.22% Health £112,186m EMTN Programme Routine Technical Update
01Jun20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
01Jun20 07:00 RNS AstraZeneca -0.22% Health £112,186m Brilinta obtains additional US approval
01Jun20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza EU CHMP opinion in pancreatic cancer
29May20 13:00 RNS AstraZeneca -0.22% Health £112,186m Enhertu DESTINY-Gastric01 results from ASCO 2020
29May20 13:00 RNS AstraZeneca -0.22% Health £112,186m Imfinzi sustained overall survival in CASPIAN
29May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Tagrisso unprecedented adjuvant lung cancer data
26May20 10:30 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
22May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Enhertu US orphan designation in gastric cancer
21May20 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca advances response to COVID-19 outbreak
20May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza approved in the US for prostate cancer
18May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Bevespi Aerosphere approved in China for COPD
18May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Enhertu US Breakthrough status for lung cancer
11May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Brazikumab rights recovered by AstraZeneca
11May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza gets broader US ovarian cancer approval
11May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Enhertu designated gastric cancer BTD
06May20 07:00 RNS AstraZeneca -0.22% Health £112,186m Farxiga approved by FDA for heart failure (HFrEF)
01May20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
29Apr20 16:00 RNS AstraZeneca -0.22% Health £112,186m Result of AGM
29Apr20 07:00 RNS AstraZeneca -0.22% Health £112,186m AZN: first-quarter 2020 results
24Apr20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza shows overall survival in prostate cancer
17Apr20 11:00 RNS AstraZeneca -0.22% Health £112,186m Changes to arrangements for AGM
14Apr20 07:00 RNS AstraZeneca -0.22% Health £112,186m Tagrisso adjuvant trial overwhelmingly positive
14Apr20 07:00 RNS AstraZeneca -0.22% Health £112,186m Koselugo (selumetinib) approved in the US for NF1
02Apr20 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divestment of Movantik completed
01Apr20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
31Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
30Mar20 07:01 RNS AstraZeneca -0.22% Health £112,186m Imfinzi approved in US for small cell lung cancer
30Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Farxiga CKD trial early stop for positive efficacy
26Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
26Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lokelma approved in Japan for hyperkalaemia
20Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
19Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza granted orphan drug designation in Japan
17Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Imfinzi confirmed overall survival in CASPIAN
12Mar20 11:00 RNS AstraZeneca -0.22% Health £112,186m Notice of AGM
12Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Update on Phase III GY004 trial for cediranib
10Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
06Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Update on Phase III DANUBE trial in bladder cancer
04Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Filing of Form 20-F with SEC
03Mar20 11:00 RNS AstraZeneca -0.22% Health £112,186m Annual Financial Report
02Mar20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
02Mar20 07:00 RNS AstraZeneca -0.22% Health £112,186m Divestment of hypertension medicines completed
27Feb20 07:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
25Feb20 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divests global rights to Movantik
19Feb20 07:00 RNS AstraZeneca -0.22% Health £112,186m Director/PDMR Shareholding
14Feb20 07:00 RNS AstraZeneca -0.22% Health £112,186m AZN: Full-year and Q4 2019 results
03Feb20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
27Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m Enhertu Phase II trial met primary endpoint
27Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m Brilinta met primary endpoint in stroke trial
27Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divests hypertension medicines
27Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca to recover brazikumab (MEDI2070)
20Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m Imfinzi, tremelimumab granted ODD in liver cancer
20Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m FDA grants Lynparza Priority Review for PROfound
13Jan20 07:01 RNS AstraZeneca -0.22% Health £112,186m Lynparza granted FDA Priority Review for PAOLA-1
13Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m Update on Epanova Phase III STRENGTH trial
06Jan20 07:01 RNS AstraZeneca -0.22% Health £112,186m Farxiga granted FDA heart failure Priority Review
06Jan20 07:00 RNS AstraZeneca -0.22% Health £112,186m Lokelma approved in China for hyperkalaemia
02Jan20 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
30Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m US FDA approved Lynparza for pancreatic cancer
23Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m Triple-combination approved in China for COPD
23Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m Enhertu (trastuzumab deruxtecan) approved in US
20Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divests rights to Arimidex and Casodex
17Dec19 18:06 RNS AstraZeneca -0.22% Health £112,186m FDA panel backs Lynparza use for pancreatic cancer
16Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m Seroquel rights agreement complete: Europe, Russia
12Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m Imfinzi approved in China for Stage III NSCLC
11Dec19 13:00 RNS AstraZeneca -0.22% Health £112,186m Trastuzumab deruxtecan achieves ORR of 60.9%
05Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza approved in China for 1L BRCAm ovarian
03Dec19 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divests Seroquel rights: US and Canada
02Dec19 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
29Nov19 07:00 RNS AstraZeneca -0.22% Health £112,186m Imfinzi granted FDA Priority Review for SCLC
21Nov19 18:15 RNS AstraZeneca -0.22% Health £112,186m Calquence approved in CLL in the US
15Nov19 07:00 RNS AstraZeneca -0.22% Health £112,186m Qtrilmet approved in the EU for treatment of T2D
14Nov19 07:00 RNS AstraZeneca -0.22% Health £112,186m FDA accepts regulatory submission for selumetinib
12Nov19 07:00 RNS AstraZeneca -0.22% Health £112,186m Anifrolumab demonstrated superiority in TULIP 2
11Nov19 07:00 RNS AstraZeneca -0.22% Health £112,186m Roxadustat pooled analyses: no increased CV risk
08Nov19 07:00 RNS AstraZeneca -0.22% Health £112,186m Roxadustat significantly increased haemoglobin
06Nov19 14:10 RNS AstraZeneca -0.22% Health £112,186m Calquence data to show improved progression-free
01Nov19 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
30Oct19 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divests rights to Seroquel and
28Oct19 15:31 RNS AstraZeneca -0.22% Health £112,186m Imfinzi and Imfinzi plus tremelimumab delayed
24Oct19 07:00 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca year-to-date and Q3 2019 results
21Oct19 07:00 RNS AstraZeneca -0.22% Health £112,186m Farxiga approved in the US to reduce the risk of
17Oct19 07:00 RNS AstraZeneca -0.22% Health £112,186m Trastuzumab deruxtecan granted FDA Priority Review
04Oct19 15:04 RNS AstraZeneca -0.22% Health £112,186m Holding(s) in Company
04Oct19 15:00 RNS AstraZeneca -0.22% Health £112,186m Holding(s) in Company
04Oct19 07:00 RNS AstraZeneca -0.22% Health £112,186m Fasenra approved in the US for self-administration
03Oct19 16:00 RNS AstraZeneca -0.22% Health £112,186m Director Declaration
01Oct19 15:00 RNS AstraZeneca -0.22% Health £112,186m Total Voting Rights
01Oct19 07:05 RNS AstraZeneca -0.22% Health £112,186m AstraZeneca divests rights for Losec to Cheplaphar
01Oct19 07:00 RNS AstraZeneca -0.22% Health £112,186m Update on US regulatory review of PT010 in COPD
30Sep19 15:30 RNS AstraZeneca -0.22% Health £112,186m Lynparza more than doubled the time without
30Sep19 07:00 RNS AstraZeneca -0.22% Health £112,186m Lynparza improved the time women lived without
Date / Time Source Company % Chg
09Jul20 07:00 RNS AstraZeneca -0.22%
Brilinta granted US FDA Priority Review for stroke
08Jul20 07:00 RNS AstraZeneca -0.22%
Lynparza approved in the EU for pancreatic cancer
01Jul20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
30Jun20 15:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
30Jun20 07:00 RNS AstraZeneca -0.22%
Selumetinib granted Japan orphan drug designation
17Jun20 15:03 RNS AstraZeneca -0.22%
Holding(s) in Company
17Jun20 15:00 RNS AstraZeneca -0.22%
Holding(s) in Company
15Jun20 07:00 RNS AstraZeneca -0.22%
Agreement to Supply Europe with COVID-19 Vaccine
11Jun20 07:00 RNS AstraZeneca -0.22%
EMTN Programme Routine Technical Update
01Jun20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
01Jun20 07:00 RNS AstraZeneca -0.22%
Brilinta obtains additional US approval
01Jun20 07:00 RNS AstraZeneca -0.22%
Lynparza EU CHMP opinion in pancreatic cancer
29May20 13:00 RNS AstraZeneca -0.22%
Enhertu DESTINY-Gastric01 results from ASCO 2020
29May20 13:00 RNS AstraZeneca -0.22%
Imfinzi sustained overall survival in CASPIAN
29May20 07:00 RNS AstraZeneca -0.22%
Tagrisso unprecedented adjuvant lung cancer data
26May20 10:30 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
22May20 07:00 RNS AstraZeneca -0.22%
Enhertu US orphan designation in gastric cancer
21May20 07:00 RNS AstraZeneca -0.22%
AstraZeneca advances response to COVID-19 outbreak
20May20 07:00 RNS AstraZeneca -0.22%
Lynparza approved in the US for prostate cancer
18May20 07:00 RNS AstraZeneca -0.22%
Bevespi Aerosphere approved in China for COPD
18May20 07:00 RNS AstraZeneca -0.22%
Enhertu US Breakthrough status for lung cancer
11May20 07:00 RNS AstraZeneca -0.22%
Brazikumab rights recovered by AstraZeneca
11May20 07:00 RNS AstraZeneca -0.22%
Lynparza gets broader US ovarian cancer approval
11May20 07:00 RNS AstraZeneca -0.22%
Enhertu designated gastric cancer BTD
06May20 07:00 RNS AstraZeneca -0.22%
Farxiga approved by FDA for heart failure (HFrEF)
01May20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
29Apr20 16:00 RNS AstraZeneca -0.22%
Result of AGM
29Apr20 07:00 RNS AstraZeneca -0.22%
AZN: first-quarter 2020 results
24Apr20 07:00 RNS AstraZeneca -0.22%
Lynparza shows overall survival in prostate cancer
17Apr20 11:00 RNS AstraZeneca -0.22%
Changes to arrangements for AGM
14Apr20 07:00 RNS AstraZeneca -0.22%
Tagrisso adjuvant trial overwhelmingly positive
14Apr20 07:00 RNS AstraZeneca -0.22%
Koselugo (selumetinib) approved in the US for NF1
02Apr20 07:00 RNS AstraZeneca -0.22%
AstraZeneca divestment of Movantik completed
01Apr20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
31Mar20 07:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
30Mar20 07:01 RNS AstraZeneca -0.22%
Imfinzi approved in US for small cell lung cancer
30Mar20 07:00 RNS AstraZeneca -0.22%
Farxiga CKD trial early stop for positive efficacy
26Mar20 07:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
26Mar20 07:00 RNS AstraZeneca -0.22%
Lokelma approved in Japan for hyperkalaemia
20Mar20 07:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
19Mar20 07:00 RNS AstraZeneca -0.22%
Lynparza granted orphan drug designation in Japan
17Mar20 07:00 RNS AstraZeneca -0.22%
Imfinzi confirmed overall survival in CASPIAN
12Mar20 11:00 RNS AstraZeneca -0.22%
Notice of AGM
12Mar20 07:00 RNS AstraZeneca -0.22%
Update on Phase III GY004 trial for cediranib
10Mar20 07:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
06Mar20 07:00 RNS AstraZeneca -0.22%
Update on Phase III DANUBE trial in bladder cancer
04Mar20 07:00 RNS AstraZeneca -0.22%
Filing of Form 20-F with SEC
03Mar20 11:00 RNS AstraZeneca -0.22%
Annual Financial Report
02Mar20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
02Mar20 07:00 RNS AstraZeneca -0.22%
Divestment of hypertension medicines completed
27Feb20 07:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
25Feb20 07:00 RNS AstraZeneca -0.22%
AstraZeneca divests global rights to Movantik
19Feb20 07:00 RNS AstraZeneca -0.22%
Director/PDMR Shareholding
14Feb20 07:00 RNS AstraZeneca -0.22%
AZN: Full-year and Q4 2019 results
03Feb20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
27Jan20 07:00 RNS AstraZeneca -0.22%
Enhertu Phase II trial met primary endpoint
27Jan20 07:00 RNS AstraZeneca -0.22%
Brilinta met primary endpoint in stroke trial
27Jan20 07:00 RNS AstraZeneca -0.22%
AstraZeneca divests hypertension medicines
27Jan20 07:00 RNS AstraZeneca -0.22%
AstraZeneca to recover brazikumab (MEDI2070)
20Jan20 07:00 RNS AstraZeneca -0.22%
Imfinzi, tremelimumab granted ODD in liver cancer
20Jan20 07:00 RNS AstraZeneca -0.22%
FDA grants Lynparza Priority Review for PROfound
13Jan20 07:01 RNS AstraZeneca -0.22%
Lynparza granted FDA Priority Review for PAOLA-1
13Jan20 07:00 RNS AstraZeneca -0.22%
Update on Epanova Phase III STRENGTH trial
06Jan20 07:01 RNS AstraZeneca -0.22%
Farxiga granted FDA heart failure Priority Review
06Jan20 07:00 RNS AstraZeneca -0.22%
Lokelma approved in China for hyperkalaemia
02Jan20 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
30Dec19 07:00 RNS AstraZeneca -0.22%
US FDA approved Lynparza for pancreatic cancer
23Dec19 07:00 RNS AstraZeneca -0.22%
Triple-combination approved in China for COPD
23Dec19 07:00 RNS AstraZeneca -0.22%
Enhertu (trastuzumab deruxtecan) approved in US
20Dec19 07:00 RNS AstraZeneca -0.22%
AstraZeneca divests rights to Arimidex and Casodex
17Dec19 18:06 RNS AstraZeneca -0.22%
FDA panel backs Lynparza use for pancreatic cancer
16Dec19 07:00 RNS AstraZeneca -0.22%
Seroquel rights agreement complete: Europe, Russia
12Dec19 07:00 RNS AstraZeneca -0.22%
Imfinzi approved in China for Stage III NSCLC
11Dec19 13:00 RNS AstraZeneca -0.22%
Trastuzumab deruxtecan achieves ORR of 60.9%
05Dec19 07:00 RNS AstraZeneca -0.22%
Lynparza approved in China for 1L BRCAm ovarian
03Dec19 07:00 RNS AstraZeneca -0.22%
AstraZeneca divests Seroquel rights: US and Canada
02Dec19 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
29Nov19 07:00 RNS AstraZeneca -0.22%
Imfinzi granted FDA Priority Review for SCLC
21Nov19 18:15 RNS AstraZeneca -0.22%
Calquence approved in CLL in the US
15Nov19 07:00 RNS AstraZeneca -0.22%
Qtrilmet approved in the EU for treatment of T2D
14Nov19 07:00 RNS AstraZeneca -0.22%
FDA accepts regulatory submission for selumetinib
12Nov19 07:00 RNS AstraZeneca -0.22%
Anifrolumab demonstrated superiority in TULIP 2
11Nov19 07:00 RNS AstraZeneca -0.22%
Roxadustat pooled analyses: no increased CV risk
08Nov19 07:00 RNS AstraZeneca -0.22%
Roxadustat significantly increased haemoglobin
06Nov19 14:10 RNS AstraZeneca -0.22%
Calquence data to show improved progression-free
01Nov19 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
30Oct19 07:00 RNS AstraZeneca -0.22%
AstraZeneca divests rights to Seroquel and
28Oct19 15:31 RNS AstraZeneca -0.22%
Imfinzi and Imfinzi plus tremelimumab delayed
24Oct19 07:00 RNS AstraZeneca -0.22%
AstraZeneca year-to-date and Q3 2019 results
21Oct19 07:00 RNS AstraZeneca -0.22%
Farxiga approved in the US to reduce the risk of
17Oct19 07:00 RNS AstraZeneca -0.22%
Trastuzumab deruxtecan granted FDA Priority Review
04Oct19 15:04 RNS AstraZeneca -0.22%
Holding(s) in Company
04Oct19 15:00 RNS AstraZeneca -0.22%
Holding(s) in Company
04Oct19 07:00 RNS AstraZeneca -0.22%
Fasenra approved in the US for self-administration
03Oct19 16:00 RNS AstraZeneca -0.22%
Director Declaration
01Oct19 15:00 RNS AstraZeneca -0.22%
Total Voting Rights
01Oct19 07:05 RNS AstraZeneca -0.22%
AstraZeneca divests rights for Losec to Cheplaphar
01Oct19 07:00 RNS AstraZeneca -0.22%
Update on US regulatory review of PT010 in COPD
30Sep19 15:30 RNS AstraZeneca -0.22%
Lynparza more than doubled the time without
30Sep19 07:00 RNS AstraZeneca -0.22%
Lynparza improved the time women lived without
Date / Time Company % Chg
09Jul20 07:00 AstraZeneca -0.22%
Brilinta granted US FDA Priority Review for stroke
08Jul20 07:00 AstraZeneca -0.22%
Lynparza approved in the EU for pancreatic cancer
01Jul20 15:00 AstraZeneca -0.22%
Total Voting Rights
30Jun20 15:00 AstraZeneca -0.22%
Director/PDMR Shareholding
30Jun20 07:00 AstraZeneca -0.22%
Selumetinib granted Japan orphan drug designation
17Jun20 15:03 AstraZeneca -0.22%
Holding(s) in Company
17Jun20 15:00 AstraZeneca -0.22%
Holding(s) in Company
15Jun20 07:00 AstraZeneca -0.22%
Agreement to Supply Europe with COVID-19 Vaccine
11Jun20 07:00 AstraZeneca -0.22%
EMTN Programme Routine Technical Update
01Jun20 15:00 AstraZeneca -0.22%
Total Voting Rights
01Jun20 07:00 AstraZeneca -0.22%
Brilinta obtains additional US approval
01Jun20 07:00 AstraZeneca -0.22%
Lynparza EU CHMP opinion in pancreatic cancer
29May20 13:00 AstraZeneca -0.22%
Enhertu DESTINY-Gastric01 results from ASCO 2020
29May20 13:00 AstraZeneca -0.22%
Imfinzi sustained overall survival in CASPIAN
29May20 07:00 AstraZeneca -0.22%
Tagrisso unprecedented adjuvant lung cancer data
26May20 10:30 AstraZeneca -0.22%
Director/PDMR Shareholding
22May20 07:00 AstraZeneca -0.22%
Enhertu US orphan designation in gastric cancer
21May20 07:00 AstraZeneca -0.22%
AstraZeneca advances response to COVID-19 outbreak
20May20 07:00 AstraZeneca -0.22%
Lynparza approved in the US for prostate cancer
18May20 07:00 AstraZeneca -0.22%
Bevespi Aerosphere approved in China for COPD
18May20 07:00 AstraZeneca -0.22%
Enhertu US Breakthrough status for lung cancer
11May20 07:00 AstraZeneca -0.22%
Brazikumab rights recovered by AstraZeneca
11May20 07:00 AstraZeneca -0.22%
Lynparza gets broader US ovarian cancer approval
11May20 07:00 AstraZeneca -0.22%
Enhertu designated gastric cancer BTD
06May20 07:00 AstraZeneca -0.22%
Farxiga approved by FDA for heart failure (HFrEF)
01May20 15:00 AstraZeneca -0.22%
Total Voting Rights
29Apr20 16:00 AstraZeneca -0.22%
Result of AGM
29Apr20 07:00 AstraZeneca -0.22%
AZN: first-quarter 2020 results
24Apr20 07:00 AstraZeneca -0.22%
Lynparza shows overall survival in prostate cancer
17Apr20 11:00 AstraZeneca -0.22%
Changes to arrangements for AGM
14Apr20 07:00 AstraZeneca -0.22%
Tagrisso adjuvant trial overwhelmingly positive
14Apr20 07:00 AstraZeneca -0.22%
Koselugo (selumetinib) approved in the US for NF1
02Apr20 07:00 AstraZeneca -0.22%
AstraZeneca divestment of Movantik completed
01Apr20 15:00 AstraZeneca -0.22%
Total Voting Rights
31Mar20 07:00 AstraZeneca -0.22%
Director/PDMR Shareholding
30Mar20 07:01 AstraZeneca -0.22%
Imfinzi approved in US for small cell lung cancer
30Mar20 07:00 AstraZeneca -0.22%
Farxiga CKD trial early stop for positive efficacy
26Mar20 07:00 AstraZeneca -0.22%
Director/PDMR Shareholding
26Mar20 07:00 AstraZeneca -0.22%
Lokelma approved in Japan for hyperkalaemia
20Mar20 07:00 AstraZeneca -0.22%
Director/PDMR Shareholding
19Mar20 07:00 AstraZeneca -0.22%
Lynparza granted orphan drug designation in Japan
17Mar20 07:00 AstraZeneca -0.22%
Imfinzi confirmed overall survival in CASPIAN
12Mar20 11:00 AstraZeneca -0.22%
Notice of AGM
12Mar20 07:00 AstraZeneca -0.22%
Update on Phase III GY004 trial for cediranib
10Mar20 07:00 AstraZeneca -0.22%
Director/PDMR Shareholding
06Mar20 07:00 AstraZeneca -0.22%
Update on Phase III DANUBE trial in bladder cancer
04Mar20 07:00 AstraZeneca -0.22%
Filing of Form 20-F with SEC
03Mar20 11:00 AstraZeneca -0.22%
Annual Financial Report
02Mar20 15:00 AstraZeneca -0.22%
Total Voting Rights
02Mar20 07:00 AstraZeneca -0.22%
Divestment of hypertension medicines completed
27Feb20 07:00 AstraZeneca -0.22%
Director/PDMR Shareholding
25Feb20 07:00 AstraZeneca -0.22%
AstraZeneca divests global rights to Movantik
19Feb20 07:00 AstraZeneca -0.22%
Director/PDMR Shareholding
14Feb20 07:00 AstraZeneca -0.22%
AZN: Full-year and Q4 2019 results
03Feb20 15:00 AstraZeneca -0.22%
Total Voting Rights
27Jan20 07:00 AstraZeneca -0.22%
Enhertu Phase II trial met primary endpoint
27Jan20 07:00 AstraZeneca -0.22%
Brilinta met primary endpoint in stroke trial
27Jan20 07:00 AstraZeneca -0.22%
AstraZeneca divests hypertension medicines
27Jan20 07:00 AstraZeneca -0.22%
AstraZeneca to recover brazikumab (MEDI2070)
20Jan20 07:00 AstraZeneca -0.22%
Imfinzi, tremelimumab granted ODD in liver cancer
20Jan20 07:00 AstraZeneca -0.22%
FDA grants Lynparza Priority Review for PROfound
13Jan20 07:01 AstraZeneca -0.22%
Lynparza granted FDA Priority Review for PAOLA-1
13Jan20 07:00 AstraZeneca -0.22%
Update on Epanova Phase III STRENGTH trial
06Jan20 07:01 AstraZeneca -0.22%
Farxiga granted FDA heart failure Priority Review
06Jan20 07:00 AstraZeneca -0.22%
Lokelma approved in China for hyperkalaemia
02Jan20 15:00 AstraZeneca -0.22%
Total Voting Rights
30Dec19 07:00 AstraZeneca -0.22%
US FDA approved Lynparza for pancreatic cancer
23Dec19 07:00 AstraZeneca -0.22%
Triple-combination approved in China for COPD
23Dec19 07:00 AstraZeneca -0.22%
Enhertu (trastuzumab deruxtecan) approved in US
20Dec19 07:00 AstraZeneca -0.22%
AstraZeneca divests rights to Arimidex and Casodex
17Dec19 18:06 AstraZeneca -0.22%
FDA panel backs Lynparza use for pancreatic cancer
16Dec19 07:00 AstraZeneca -0.22%
Seroquel rights agreement complete: Europe, Russia
12Dec19 07:00 AstraZeneca -0.22%
Imfinzi approved in China for Stage III NSCLC
11Dec19 13:00 AstraZeneca -0.22%
Trastuzumab deruxtecan achieves ORR of 60.9%
05Dec19 07:00 AstraZeneca -0.22%
Lynparza approved in China for 1L BRCAm ovarian
03Dec19 07:00 AstraZeneca -0.22%
AstraZeneca divests Seroquel rights: US and Canada
02Dec19 15:00 AstraZeneca -0.22%
Total Voting Rights
29Nov19 07:00 AstraZeneca -0.22%
Imfinzi granted FDA Priority Review for SCLC
21Nov19 18:15 AstraZeneca -0.22%
Calquence approved in CLL in the US
15Nov19 07:00 AstraZeneca -0.22%
Qtrilmet approved in the EU for treatment of T2D
14Nov19 07:00 AstraZeneca -0.22%
FDA accepts regulatory submission for selumetinib
12Nov19 07:00 AstraZeneca -0.22%
Anifrolumab demonstrated superiority in TULIP 2
11Nov19 07:00 AstraZeneca -0.22%
Roxadustat pooled analyses: no increased CV risk
08Nov19 07:00 AstraZeneca -0.22%
Roxadustat significantly increased haemoglobin
06Nov19 14:10 AstraZeneca -0.22%
Calquence data to show improved progression-free
01Nov19 15:00 AstraZeneca -0.22%
Total Voting Rights
30Oct19 07:00 AstraZeneca -0.22%
AstraZeneca divests rights to Seroquel and
28Oct19 15:31 AstraZeneca -0.22%
Imfinzi and Imfinzi plus tremelimumab delayed
24Oct19 07:00 AstraZeneca -0.22%
AstraZeneca year-to-date and Q3 2019 results
21Oct19 07:00 AstraZeneca -0.22%
Farxiga approved in the US to reduce the risk of
17Oct19 07:00 AstraZeneca -0.22%
Trastuzumab deruxtecan granted FDA Priority Review
04Oct19 15:04 AstraZeneca -0.22%
Holding(s) in Company
04Oct19 15:00 AstraZeneca -0.22%
Holding(s) in Company
04Oct19 07:00 AstraZeneca -0.22%
Fasenra approved in the US for self-administration
03Oct19 16:00 AstraZeneca -0.22%
Director Declaration
01Oct19 15:00 AstraZeneca -0.22%
Total Voting Rights
01Oct19 07:05 AstraZeneca -0.22%
AstraZeneca divests rights for Losec to Cheplaphar
01Oct19 07:00 AstraZeneca -0.22%
Update on US regulatory review of PT010 in COPD
30Sep19 15:30 AstraZeneca -0.22%
Lynparza more than doubled the time without
30Sep19 07:00 AstraZeneca -0.22%
Lynparza improved the time women lived without